Markets are Closed
NVO
Novo Nordisk A/S
Open
—
Previous Open
High
69.73
Previous High
Low
69.29
Previous Low
Close
69.46
Previous Close
Volume
588,455
Previous Volume
Company Profile
Description
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.
Exchange
New York Stock Exchange
List Date
January 02, 1990
CEO
Lars Fruergaard Jorgensen
Employees
43,161
Related Stocks
Financials
Revenue
17.94B
Earnings
7.72B
20B
17B
13B
10B
6B
2017
2017
2018
2018
Splits
| January 08, 2014 | 0.20% |
| December 17, 2007 | 0.50% |
| April 11, 2001 | 0.40% |
Dividends
| April 07, 2021 | $0.68 |
| August 25, 2020 | $0.37 |
| April 07, 2020 | $0.56 |
| April 07, 2020 | $0.56 |
| August 27, 2019 | $0.32 |
| April 02, 2019 | $0.56 |
| August 28, 2018 | $0.33 |
| April 03, 2018 | $0.58 |
| August 29, 2017 | $0.34 |
| April 04, 2017 | $0.48 |
| August 23, 2016 | $0.33 |
| March 30, 2016 | $0.70 |
| March 31, 2015 | $0.53 |
| April 02, 2014 | $0.61 |
| April 02, 2013 | $0.45 |
Related News
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
Feb 05, 2020 @ 16:11
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019....
finance yahooNovo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
Nov 19, 2019 @ 14:23
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases....
finance yahooNew "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic
Nov 19, 2019 @ 13:50
PHILADELPHIA, Nov. 19, 2019 /PRNewswire/ -- More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of neighborhoods that may make people more – or less – prone to developing type 2 diabetes...
finance yahoo
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
Nov 18, 2019 @ 12:46
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same....
finance yahoo
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
Nov 15, 2019 @ 14:23
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU....
finance yahoo
4 Big Drugmakers to Bet on After a Great Earnings Season
Nov 15, 2019 @ 11:41
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry....
finance yahoo
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
Nov 14, 2019 @ 15:43
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics...
finance yahoo
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
Nov 14, 2019 @ 14:44
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes....
finance yahoo
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
Nov 13, 2019 @ 18:54
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk...
finance yahoo
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Nov 11, 2019 @ 15:32
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J...
finance yahooAll data provided on Polygon is provided for informational purposes only, and is not intended for trading or investing purposes.
Copyright © 2021, Polygon.io, Inc. All Rights Reserved.
TradingView Lightweight Chart: Copyright (с) 2020 TradingView, Inc. https://www.tradingview.com/